Cargando…
2452. Treatment and Outcomes of Daptomycin-Nonsusceptible Methicillin-Resistant Staphylococcus aureus Bloodstream Infections
BACKGROUND: Daptomycin (dap) is approved as an alternative to vancomycin (van) for therapy of methicillin-resistant Staphylococcus aureus (MRSA) bloodstream infection (BSI). Cases of therapy failure associated with the emergence of daptomycin-nonsusceptible (DNS) MRSA strains have been documented. I...
Autores principales: | Hadid, Hind, Bardossy, Ana Cecilia, Misikir, Helina, Perri, Mary Beth, Zervos, Marcus, Herc, Erica |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6255085/ http://dx.doi.org/10.1093/ofid/ofy210.2105 |
Ejemplares similares
-
1222. Risk Factors and Outcomes for Daptomycin Nonsusceptible Methicillin-Resistant Staphylococcus aureus Bloodstream Infections
por: Hadid, Hind, et al.
Publicado: (2018) -
711. Molecular Epidemiology of Daptomycin Nonsusceptibility in Methicillin-Resistant Staphylococcus aureus (MRSA) Bacteremia
por: Sundaram, Ayesha, et al.
Publicado: (2018) -
1208. Impact of Admission to an Inpatient Infectious Disease Unit on Methicillin-Resistant Staphylococcus aureus Bloodstream Infections
por: Mirza, Zainab Farooqui, et al.
Publicado: (2018) -
627. Molecular Epidemiology of Daptomycin-resistant Staphylococcus aureus Causing Bloodstream Infections
por: Gudipati, Smitha, et al.
Publicado: (2019) -
1027. Outpatient Parenteral Antimicrobial Therapy (OPAT) in Injection Drug Users (IDUs): Is It Safe?
por: Rizvi, Hira, et al.
Publicado: (2018)